Tag: protection

MIAMI, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) --  GadCapital, a leading direct lender in the digital lending space, announces the expansion of its payday loans online no credit check platform, specifically designed to serve borrowers seeking quick cash solutions for emergency situations. The company's innovative micro-lending approach offers loan amounts ranging from $100 to $500 with guaranteed approval for qualifying applicants, positioning itself as a targeted alternative in the rapidly growing online lending market.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Flywire Corporation (NASDAQ:FLYW), Lockheed Martin Corporation (NYSE:LMT), and Sable Offshore Corporation (NYSE:SOC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

TABER, ALBERTA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces it has signed a second significant food grade contract.

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.